Celyad Oncology SA (EBR:CYAD)
0.2200
-0.0100 (-4.35%)
Last updated: Oct 24, 2025, 11:59 AM CET
Celyad Oncology Revenue
Celyad Oncology had revenue of 14.00K EUR in the half year ending June 30, 2025, a decrease of -68.18%. This brings the company's revenue in the last twelve months to 186.00K, up 158.33% year-over-year. In the year 2024, Celyad Oncology had annual revenue of 186.00K with 82.35% growth.
Revenue
186.00K
Revenue Growth
+158.33%
P/S Ratio
51.26
Revenue / Employee
10.33K
Employees
19
Market Cap
9.53M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 186.00K | 84.00K | 82.35% |
| Dec 31, 2023 | 102.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 5.00K | -1.00K | -16.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UCB SA | 6.85B |
| argenx SE | 2.66B |
| Fagron NV | 918.75M |
| Ion Beam Applications | 585.76M |
| European Medical Solutions | 49.47M |
| Biocartis Group NV | 47.69M |
| Hyloris Pharmaceuticals | 8.46M |
| Nyxoah | 4.93M |